Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Increase in lung cancer resection rate linked to increased investment in thoracic surgical expertise

Increased investment in specialist thoracic surgical expertise can lead to a significant rise in the lung cancer resection rate, based on data from England between 2008 and 2009 that was presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer (IASLC).

6 Jul 2011

New CRM simulation model for Canadian Partnership Against Cancer

If Canada's smoking rates were cut by half to an average national rate of 11% within five years, it would result in 35,900 fewer cases of lung cancer by 2030 and save $656 million in treatment costs, according to analysis using a new web-enabled platform developed for the Canadian Partnership Against Cancer and presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

6 Jul 2011

Stereotactic ablative radiotherapy improves median survival for elderly Dutch NSCLC patients

New developments such as stereotactic ablative radiotherapy and improvements in surgical care in early-stage lung cancer have led to large survival gains for elderly Dutch patients, according to a population-based study presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

6 Jul 2011

Older people, women and minorities enrolled less frequently in lung cancer drug trials

Women, older people and minorities are enrolled less frequently in lung cancer drug trials and the numbers do not reflect the prevalence of lung cancer in these populations, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

6 Jul 2011

Patients with high EGFR expression more likely to benefit from cetuximab plus chemotherapy

High epidermal growth factor receptor expression was a good predictor of which lung cancer patients would survive longer when cetuximab was added to first-line chemotherapy, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

5 Jul 2011

PET imaging technique may identify TKI-responsive lung cancer

A non-invasive PET imaging technique may identify lung cancers that respond best to tyrosine kinase inhibitors (TKIs), allowing doctors to better select patients for personalized therapy, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

5 Jul 2011

LCMC finds 9.6% of lung cancer patients with ALK rearrangement

ALK rearrangement has been found in 9.6% of lung cancer patients tested in the Lung Cancer Mutation Consortium, and MET amplification in another 4.1%, reflecting how many patients might benefit from targeted therapies such as crizotinib, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

5 Jul 2011

Erlotinib phase III study results on lung cancer presented at IASLC conference

In the first phase III study to include Western lung cancer patients, first-line treatment with erlotinib (Tarceva) nearly doubled progression-free survival compared with chemotherapy, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

5 Jul 2011

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

Genentech, a member of the Roche Group, announced today that, during a U.S. Food and Drug Administration (FDA) hearing, the FDA's Oncologic Drugs Advisory Committee (ODAC) recommended that the FDA withdraw its approval of Avastin in combination with paclitaxel chemotherapy for previously untreated HER2-negative metastatic breast cancer.

30 Jun 2011

Pfizer to present PF-299 and crizotinib clinical trial data on ALK at WCLC 2011

Pfizer Inc. will present early and mid-stage data from its lung cancer portfolio, including PF-00299804 an investigational, oral, pan-HER inhibitor; and crizotinib, an investigational, oral, first-in-class compound that inhibits the anaplastic lymphoma kinase, or ALK, at the International Association for the Study of Lung Cancer's 14th World Conference on Lung Cancer, July 3-7 in Amsterdam, The Netherlands.

28 Jun 2011

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

Amgen today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand the indication for XGEVA (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases.

28 Jun 2011

Twelve institutions receive NPCRC and American Cancer Society grants for palliative care research

The American Cancer Society and the National Palliative Care Research Center (NPCRC) are awarding $2 million in research grants to researchers at 12 institutions for studies aimed at reducing suffering for seriously ill patients and their family caregivers.

22 Jun 2011

TESARO secures $101M in Series B financing

TESARO, Inc., an oncology-focused biopharmaceutical company, today announced that it has secured $101 million in a Series B financing to advance and expand the Company's cancer product portfolio.

21 Jun 2011

Sunshine enters Adva-27a cancer research and development agreement with The Jewish General Hospital

Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Jewish General Hospital, one of McGill University's Hospital Centers, to conduct the necessary research and development to advance Sunshine's lead compound, Adva-27a, through the various stages of preclinical studies and Phase I clinical trials.

17 Jun 2011

Reovirus with paclitaxel, carboplatin can treat metastatic non-small cell lung cancer

A type of virus known as the human reovirus possesses a remarkable trait: It can replicate inside and kill cancer cells that feature a common mutation, while leaving the body's normal cells alone.

15 Jun 2011

UC Davis, Jackson Laboratory and NCI partner for human clinical trials on cancer

About nine out of 10 new cancer drugs successfully clear preclinical development hurdles, but then they fail in human clinical testing. A new partnership facilitated by SAIC-Frederick Inc. aims to help change that outcome.

13 Jun 2011

FDA accepts ZIOPHARM's IND for ZIN ATI-001 to treat melanoma

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that the U.S. Food & Drug Administration has accepted the Company's investigational new drug application to begin clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate also known as Ad-RTS-IL-12 + AL, in oncology.

10 Jun 2011

Clovis, Avila select CO-1686 drug candidate for EGFR Mutant-Selective Inhibitor program

Avila Therapeutics, Inc. a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced that it has achieved a significant goal in its alliance with Clovis Oncology, Inc.

9 Jun 2011

Patient enrollment complete in cilengitide Phase III study against glioblastoma

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that patient enrollment in the global pivotal Phase III clinical study CENTRIC has been completed.

9 Jun 2011

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

ZIOPHARM Oncology, Inc. announced today that Douglas J. Schwartzentruber, MD, FACS, of the Indiana University Health Goshen Center for Cancer Care, presented initial positive clinical results from the first-ever treatment demonstrating control over transgene encoding of a therapeutic anticancer protein in humans using a small molecule activator ligand.

7 Jun 2011

Small Cell Lung Cancer News and Research

Increase in lung cancer resection rate linked to increased investment in thoracic surgical expertise

New CRM simulation model for Canadian Partnership Against Cancer

Stereotactic ablative radiotherapy improves median survival for elderly Dutch NSCLC patients

Older people, women and minorities enrolled less frequently in lung cancer drug trials

Patients with high EGFR expression more likely to benefit from cetuximab plus chemotherapy

PET imaging technique may identify TKI-responsive lung cancer

LCMC finds 9.6% of lung cancer patients with ALK rearrangement

Erlotinib phase III study results on lung cancer presented at IASLC conference

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

Pfizer to present PF-299 and crizotinib clinical trial data on ALK at WCLC 2011

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

Twelve institutions receive NPCRC and American Cancer Society grants for palliative care research

TESARO secures $101M in Series B financing

Sunshine enters Adva-27a cancer research and development agreement with The Jewish General Hospital

Reovirus with paclitaxel, carboplatin can treat metastatic non-small cell lung cancer

UC Davis, Jackson Laboratory and NCI partner for human clinical trials on cancer

FDA accepts ZIOPHARM's IND for ZIN ATI-001 to treat melanoma

Clovis, Avila select CO-1686 drug candidate for EGFR Mutant-Selective Inhibitor program

Patient enrollment complete in cilengitide Phase III study against glioblastoma

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News